These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16255668)

  • 21. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antipsychotic drugs. Risk factors for diabetes].
    Stip E; Tranulis C; Légaré N; Poulin MJ
    Presse Med; 2003 Oct; 32(34):1612-7. PubMed ID: 14576587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring.
    De Hert M; van Eyck D; De Nayer A
    Int Clin Psychopharmacol; 2006 Mar; 21 Suppl 2():S11-5. PubMed ID: 16601508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Schizophrenia, obesity, and antipsychotic medications: what can we do?
    Citrome L; Vreeland B
    Postgrad Med; 2008 Jul; 120(2):18-33. PubMed ID: 18654065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic syndrome and mental illness.
    Newcomer JW
    Am J Manag Care; 2007 Nov; 13(7 Suppl):S170-7. PubMed ID: 18041878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
    Miller LJ
    Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychiatric medication-induced obesity: a review.
    Schwartz TL; Nihalani N; Jindal S; Virk S; Jones N
    Obes Rev; 2004 May; 5(2):115-21. PubMed ID: 15086865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002.
    Reist C; Mintz J; Albers LJ; Jamal MM; Szabo S; Ozdemir V
    J Clin Psychopharmacol; 2007 Feb; 27(1):46-51. PubMed ID: 17224711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication.
    Gregoor JG; van der Weide J; Mulder H; Cohen D; van Megen HJ; Egberts AC; Heerdink ER
    J Clin Psychopharmacol; 2009 Feb; 29(1):21-5. PubMed ID: 19142102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
    McIntyre RS; Jerrell JM
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between antipsychotic drugs and diabetes.
    Holt RI; Peveler RC
    Diabetes Obes Metab; 2006 Mar; 8(2):125-35. PubMed ID: 16448516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic abnormalities associated with atypical antipsychotics: a case report and alert.
    Yamauchi T; Tice A
    Hawaii Med J; 2007 Jan; 66(1):12-3. PubMed ID: 17381036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.
    Citrome LL; Holt RI; Zachry WM; Clewell JD; Orth PA; Karagianis JL; Hoffmann VP
    Ann Pharmacother; 2007 Oct; 41(10):1593-603. PubMed ID: 17785613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment.
    Cohen D; Dekker JJ; Peen J; Gispen-de Wied CC
    Eur Neuropsychopharmacol; 2006 Apr; 16(3):187-94. PubMed ID: 16263247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Schizophrenia, the metabolic syndrome and diabetes.
    Holt RI; Peveler RC; Byrne CD
    Diabet Med; 2004 Jun; 21(6):515-23. PubMed ID: 15154933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapeutic options for weight management in schizophrenic patients treated with atypical antipsychotics].
    Cordes J; Sinha-Röder A; Kahl KG; Malevani J; Thuenker J; Lange-Asschenfeldt C; Hauner H; Agelink MW; Klimke A
    Fortschr Neurol Psychiatr; 2008 Dec; 76(12):703-14. PubMed ID: 18924059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
    DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
    Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents.
    Schneiderhan ME; Batscha CL; Rosen C
    Pharmacotherapy; 2009 Aug; 29(8):975-87. PubMed ID: 19637951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implementation of monitoring and management guidelines for second-generation antipsychotics.
    Sernyak MJ
    J Clin Psychiatry; 2007; 68 Suppl 4():14-8. PubMed ID: 17539695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipsychotic drugs and diabetes.
    McIntyre RS
    CMAJ; 2003 Mar; 168(6):673. PubMed ID: 12642417
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.